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LETTER TO THE EDITOR
Management of biological
therapies for chronic plaque
psoriasis during COVID-19
emergency in Italy
Dear Editor,
The coronavirus disease 2019 (COVID-19), caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infec-
tion, is creating an unprecedented global public health emergency
with the continuous growth of infected individuals worldwide.1
Italy was one of the first European countries to face the first wave
of infection outside mainland China.2 The first case of COVID-
19 was confirmed in Lombardy on 20 February 2020, and subse-
quently, a rapid increase in the number of detected cases was
observed, spreading through Italy and the rest of Europe.3 As of
22 April, confirmed COVID-19 cases in Italy were 183 957.2,4
Because of the impaired immunologic status of patients with
psoriasis, their clinical management is challenging in the pan-
demic, particularly for those using biologics inhibiting key patho-
genic cytokines such as TNF-a, IL-17, IL-12/23 or IL-23.5–6
To date, there is neither an agreement nor a study sustaining
the impact of continuing or stopping biologics in psoriatic
patients during the COVID-19 pandemic.7–10
The PSO-BIO-COVID is an observational, multicentric study,
supported by the Italian Society of Dermatology (SIDeMaST),
aimed at evaluate the impact of SARS-CoV-2 infection on the
management of patients with psoriasis in Italy, during the first
year of the pandemic.
Patients with moderate-to-severe chronic plaque psoriasis,
aged >18 years, undergoing treatment with any biological agent
as of 22 February 2020, were eligible.
Data on biological agent used for treatment and any suspension
and/or lengthening of time intervals (LTIs) for treatment admin-
istration between 22 February and 22 April 22 2020 have been col-
lected in a standardized data collection system through face-to-
face, remote visits or via email. Frequency and percentages on the
total number of centres and patients were the analyses performed.
The study was approved by the National Ethical Committee
for COVID-19-related studies at INMI Lazzaro Spallanzani
IRCCS, with the Dermatology Unit-Fondazione Policlinico Tor
Vergata as the coordinating centre.
A total of 12 807 psoriatic patients from 33 specialized derma-
tologic centres were included in the study. 328 patients (2.6%)
stopped treatment during the observation period without con-
sulting their dermatologist mainly because of fearing high conta-
gious risk; 233 (1.8%) interrupted their therapy after consulting
their dermatologist mainly because of suspected infection or con-
tact with the SARS-CoV-2 as they were professional healthcare
providers or they have had a contact with SARS-CoV-2+ subjects
(Table 1). Discontinuation rates ranged from 1.4% for patients
using guselkumab to 5.5% for those treated with infliximab, when
the decision was taken by the patients, while ranged between 0.5%
for ixekizumab-treated patients and 2.8% for adalimumab-treated
when the decision was taken after dermatological consultation.
Table 1 Number and percentage of psoriatic patients treated with a biological agent in Italy. Period: 22 February 2020–22 April 2020
ADA ETA INF UST SEC IXE BRO GUS TIL RIS Total
Total patients 3045 1645 343 2638 2417 1586 297 628 16 192 12 807
Mean % of treated patients
for each biological drugs
23.8% 12.8% 2.7% 20.6% 18.9% 12.4% 2.3% 4.9% 0.1% 1.5 100%
Patients stopping therapy
autonomously†
90 (3.0%) 49 (3.0%) 19 (5.5%) 72 (2.7%) 49 (2.0%) 32 (2.0%) 5 (1.7%) 9 (1.4%) 0 3 (1.6%) 328 (2.6%)
Patients stopping therapy
after consulting with
the physician†
85 (2.8%) 30 (1.8%) 10 (2.9%) 21 (0.8%) 36 (1.5%) 8 (0.5%) 5 (1.7%) 13 (2.1%) 0 4 (2.1%) 233 (1.8%)
Patients’ LTIs of therapy
autonomously†
47 (1.5%) 61 (3.7%) 5 (1.5%) 28 (1.1%) 27 (1.1%) 9 (0.6%) 2 (0.7%) 4 (0.6%) 0 2 (1.0%) 185 (1.4%)
Patients’ LTIs of therapy
after consulting
with the physician†
25 (0.8%) 6 (0.4%) 11 (3.2%) 26 (1.0%) 10 (0.4%) 26 (1.6%) 1 (0.3%) 5 (0.8%) 0 4 (2.1%) 114 (0.9%)
ADA, adalimumab; BRO, brodalumab; ETA, etanercept; GUS, gusesslkumab; INF, infliximab; IXE, ixekizumab; LTIs, lengthening of time intervals; RIS,
risankizumab; SEC, secukinumab; TIL, tildrakizumab; UST, ustekinumab.
†Percentages are calculated on the total number of patients.
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An additional 185 (1.4%) patients have autonomous LTIs of
their therapy, and further 114 (0.9%) did the same but after con-
sulting their reference centre. The risk and fear of the contagious
were the most frequently reported reasons for LTIs the treatment.
This observational study included patients across Italy having
a large variability of SARS-CoV-2 infection incidence. Centres
were highly representative of the Italian distribution of SARS-
CoV-2 during the observation period, ranging from cities like
Bergamo or Milan, in Lombardy, having more than 20,000 con-
firmed diagnoses of COVID-19, to Cagliari (Sardinia) and
Palermo (Sicily) where less than 500 cases were observed in the
period when this observation was performed.4
The low number of patients who have interrupted treatment
or have LTIs for their treatment at the peak of the infection
seems a clear signal that neither the patient nor their reference
physician felt this as an option ensuring a satisfactory balance
between the risks and potential benefits.
This outcome highlights the importance of a continuous and
trusting relationship between the patient and the medical staff
who is taking care of his/her psoriasis. Patients and dermatolo-
gists are satisfied using biologics for psoriasis treatment. Thus,
both are reluctant to interrupt biological therapy if no con-
traindications occurred.
Further details on the incidence of COVID-19 disease in
patients with chronic plaque psoriasis treated with biological
agents, clinical course and outcomes of patients who developed
SARS-CoV-2 infection or who have been exposed to someone
with laboratory-confirmed COVID-19 will be obtained by the
ongoing investigation by the PSO-BIO-COVID study group.
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